MedTrace Logo

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

NCT00300807 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2007-03-07

No results posted yet for this study

Summary

1. Evaluate the safety, tolerability, and virologic activity of escalating single (and multiple) doses of XTL6865, a mixture (1:1) of two human monoclonal antibodies (HCV-AbXTL68 and HCV-AbXTL65), in patients with chronic hepatitis C virus infection.
2. Assess the pharmacokinetics of XTL6865 in the presence and absence of viral infection.

Conditions

  • Hepatitis C

Interventions

DRUG

XTL 6865

Sponsors & Collaborators

  • XTL Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • John Andrews, PhD · XTL Biopharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Completion
2007-04-30

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00300807 on ClinicalTrials.gov